Hepatoblastoma survival and the prognostic role of cancer stem cell markers by Fawzy, Mohamed et al.
International Journal of Cancer Therapy and Oncology
www.ijcto.org
Copyright © Fawzy et al. ISSN 2330-4049
Mohamed Fawzy1*, Abeer Bahnassy2, Mohamed El-Wakil3, Ahmed Abdel-Sayed4
1Department of Pediatric Oncology, National Cancer Institute (NCI), Cairo University, Egypt.
2Pathology Department, NCI, Cairo University, Egypt.
3Department of Clinical Oncology, Faculty of Medicine Beni-Suef University, Egypt.
4Department of Surgical Oncology, NCI, Cairo University, Egypt.
Received October 19, 2013; Revised December 04, 2013; Accepted December 05, 2013; Published Online December 15, 2013
Original Article
Abstract
Purpose: Hepatoblastoma (HB) is an embryonal tumor of the liver that occurs in infants and young children. Complete surgical
resection and cisplatin-containing chemotherapy are crucial for cure in HB. Cancer stem cells (CSCs) constitute a newly identi-
fied subpopulation, which may differentiate into heterogeneous progenies of malignant cells. The aim of this study was to assess
the survival outcome and the prognostic value of CSCs markers (CD133, CD90 and CD44) in a cohort of HB patients from
Egypt. Methods: Disease status of 43 HB patients was evaluated at the main checkpoints of therapy and during follow-up.
Treatment included surgical tumor resection and systemic chemotherapy (cisplatin, 5-fluorouracil, doxorubicin, and vincris-
tine). Protein and RNA expressions of CD44, CD 90 and CD 133 were assessed by immunohistochemistry and quantitative PCR.
Results: The OS for all patients was 58.2 at 4 years. Patients with localized disease stages (I&II) had a better OS than those with
advanced stages (III&IV) (81.9% versus 30%, p<0.001). Total surgical resection was superior to incomplete/no resection (83.8%
versus 25.2 %; p<0.001). The OS was significantly correlated with tumor response (p<0.001) and each of CD44, CD 90, CD 133
expression (p<0.001) whereas reduced DFS was associated with CD44 and CD133 expression (p<0.001). Conclusion: Localized
disease is associated with higher OS than more advanced stages III and IV. Complete surgical resection facilitated with systemic
preoperative chemotherapy in initially irresectable cases can improve survival in HB while CSC markers (CD133, 44, and 90)
can predict survival and response to treatment in HB patients.
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Introduction
Benign and malignant liver tumors account for 1–2% of all
pediatric tumors. However, recent data suggest that their
incidence may be increasing at 5% annually.1-3 Hepatoblas-
toma (HB) is a rare embryonal tumor of the liver forming the
most common childhood liver cancer in infants and young
children with a median age of 16 months at diagnosis.4,5 A
birth weight less than 1,000 grams is associated with strongly
increased risk of HB, while a moderately increased risk of
hepatoblastoma was found with younger maternal age, ma-
ternal smoking, infertility medications, and with higher ma-
ternal pregnancy body mass index.6 Ninety percent of pa-
tients with HB have a serum tumor marker alpha fetoprotein
(AFP), which correlates with disease activity. Both AFP level
at diagnosis and its rate of declining during treatment should
be compared to the corresponding age-adjusted values.7
Both complete surgical resection and cisplatin-containing
chemotherapy are crucial in achieving cure in HB. Radical
resection can be obtained either by partial hepatectomy or
with orthotopic liver transplant (OLT).8 Several histological
subtypes of HB are known, including the wholly epithelial
tumors, with pure fetal and mixed fetal/embryonal histology;
mixed epithelial and mesenchmyal tumors; and several types
of transitional, small and large cell undifferentiated tumors.9
This heterogeneity may explain their variable clinical be-
havior and reflects the distinct patterns of hepatic embryo-
genesis suggesting stem cell origin.10
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Cancer stem cells (CSCs) are newly identified subpopulations
isolated from several tumor types that possess stem cell
properties and may differentiate into heterogeneous proge-
nies of malignant cells. They are probably the progenitor cells
that undergo unknown genetic mutations and lose potential
for tissue repair, but retain stem cell characteristics, such as
self-renewal and plasticity to differentiate into different cell
types in tumor tissues. CSCs thought to be responsible for
tumor development, resistance to treatment, metastasis and
relapse. A better understanding of CSC pathobiology may aid
in developing novel directed therapies against such cells.10-12
Few reports addressed the role of CSCs in HB. Some markers
as CD133 and CD44 were used to detect HB-CSCs in cultured
human HB cells, while CD90 was reported to be a CSC
marker in hepatocellular carcinoma.13-14 CD133; a cell surface
glycoprotein (prominin-1) that has been used as a marker for
immature hematopoietic stem cells or progenitor cells while
CD90 (Thy-1) is a glysyl-phosphatidyl-inosital
(GPI)-anchored glycoprotein expressed in bone mar-
row-derived mesenchymal stem cells and hepatic stem cells
progenitors. CD44 is a cell surface adhesion molecule medi-
ating multiple signaling pathways which has been used as a
CSC marker in leukemia, head and neck cancer, pancreatic,
breast, and prostate cancer.15 The aim of this study was to
evaluate the outcome in a cohort of Egyptian children with
HB and to define the prognostic predictive value of CSCs
markers (CD133, CD90 and CD44) in relation to survival,
response to treatment and other prognostic factors.
Patients and Methods
Patients
This study included 43 HB patients who were diagnosed and
treated at the Pediatric Oncology Department, National
Cancer Institute (NCI), Cairo University between 2007 and
2012. All patients were newly diagnosed children below the
age of 18 years on diagnosis, with HB of any stage, and were
not previously treated elsewhere. Study protocol was ap-
proved by The Institutional Review Board (IRB) of the NCI
which was in accordance with the 2007 declaration of Hel-
sinki.
Workup and Evaluation
Histopathology and survival data of the patients under study
were systematically reviewed and verified. Full history re-
view, clinical examination and laboratory tests were done
including complete blood picture, liver and kidney functions,
and alpha-fetoprotein (AFP). Abdominal ultrasound and
enhanced computerized tomography (CT) of the abdomen
and pelvis were essentially done as baseline for all patients to
determine the extent of involved parenchyma, and the pres-
ence or absence of macro vascular compression, displacement
or invasion. The radiographic appearance of the tumor at
diagnosis “PRETEXT” was used to assign the pretreatment
extent of the tumor and “POST-TEXT” for patients received
preoperative chemotherapy.16 All patients had also baseline
CT chest and bone scan as part of their disease staging ac-
cording to the Children’s Oncology Group (COG) staging
system as all stages from I to IV were represented among our
patients.17 Evaluation of disease response was reviewed using
Response Evaluation Criteria in Solid Tumors (RECIST).18
Tumor marker AFP level and imaging studies were carried
out at the main checkpoints of therapy; post induction
treatment, following definitive surgery, by end of treatment
protocol and at regular intervals during follow up or as
elsewhere required for evaluating a suspected event (pro-
gression/recurrence).
Treatment
Therapeutic approach included surgical resection of the pri-
mary tumor (segmentecomy/lobectomy) either at initial
presentation whenever technically feasible or following up-
front chemotherapy for inoperable tumors. Combined
chemotherapy in form of cisplatin, 5-fluorouracil, doxorubi-
cin and vincristine was given on adjuvant basis for patients
with initially resected tumors (non-pure fetal stage I or posi-
tive margin stage II disease), or as neoadjuvant treatment for
stage III and stage IV patients in accordance to COG guide-
lines.19 Lacking the facility and affordability, OLT was not an
option in any of the studied patients.
Immunohistochemistry (IHC)
For each case, the most representative paraffin block was
identified by examination of hematoxylin and eosin (H/E)
stained slides. Determination of tumor: normal cell ratio was
done for each sample and only samples including ≥75% neo-
plastic cells in the sections were selected. From each tumor
block, 4 μm thick sections (3 sections) were cut onto positive
charged slides to be used for IHC analysis. Another 5 μm
thick sections (5 sections) were cut into a sterile Eppindorff
tube for molecular studies. Slides were de-paraffinized in
xylene followed by a series of graded ethanol. Antigen re-
trieval was performed by pressure cooking for 2 minutes in
citrate buffer pH6.0. Endogenous peroxidases were blocked
with 0.3% hydrogen peroxide and non-specific binding was
blocked with normal goat serum. The cells were then reacted
for 24 h at 40C with the primary antibody to: CD133 (mouse
anti- human CD133, 1:500), CD90 (mouse anti-human CD90,
1:100) and CD44 (mouse anti- human CD44, 1:50) (all from
Abcam, MA, USA); then with the secondary antibody (En-
Vision System/HRP, Dako, Tokyo, Japan) for 1 hour. After
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washing with PBS, sections were colored with DAB, coun-
terstained with hematoxylin and examined microscopically.
Cases of breast and hepatocellular carcinomas were used as
positive controls. A negative control was obtained by omit-
ting the primary antibodies. The staining intensity was noted
but not factored, as differing age of donor blocks and varia-
tion in fixation methods can impact on staining intensity. A
case was considered positive, for CD133, CD44 or CD90, if
brown membranous and/or cytoplasmic immunostaining was
detected in >10% of the cells.13-14
RNA Extraction
RNA was extracted from the representative sections of the
tumor and normal tissues. Total RNA was isolated using
RNeasy Mini Kit (Qiagen, Milan, Italy) and retro-transcribed
using iScript TM cDNA Synthesis Kit (Bio-Rad, Milano, Italy)
according to manufacturer’s instructions. Extracted RNA was
dissolved in diethyl pyrocarbonate-treated water containing
10 mmol/l of MgCl2 and incubated with 100 μg/ml of
RNase-free DNase I for 30 minutes at 37°C to eliminate con-
taminated DNA. The reaction was stopped by heating the
RNA at 95°C for 5 minutes after the addition of EDTA to a
final concentration 30mmol/l.
Quantitative real-time PCR (q-RT-PCR)
Real-time quantitative (q-RT-PCR) analysis was performed
with the SYBR Green PCR Master Mix using a stratagene
MAX3000P according to the manufacturer's instructions
(Applied Biosystems, Inc., Foster City, CA, USA). Primer
sequences for CD133, CD44, and β-actin were as follows:
CD133 (sense, GCTTTGCAATCTCCCTGTTG; antisense,
TTGATCCGGGTTCTTACCTG), CD44 (sense, CGGACAC-
CATGGACAAGTTT; antisense, CACGTGGAATACAC-
CTGCAA), and β-actin (sense, ACAGAGCCTCGCCTTTGC;
antisense, GCGGCGATA TCATCATCC).
PCR was performed in a final volume of 25 μl with a SYBR
Green PCR Master Mix using 1 μl cDNA, 400 nM of each
primer for the respective genes. Cycling conditions were 50°C
for 2 minutes and 95°C for 10 minutes, followed by 40 cycles
at 95°C for 15 sec and 60°C for 1 minute. Real-time PCR
assays were carried out in duplicate for each sample and mean
values were used for the calculation of the mRNA levels.
Real-time quantitative RT-PCR for CD90 was performed
using Taqman gene expression probes (Applied Biosystems).
Expression of mRNA was assessed using standard curve and
normalized to β-actin. Data were expressed as relative ex-
pression units.20-21
Statistical Methods
Data was analyzed using SPSS win statistical package version
17 (SPSS Inc., Chicago, IL). Numerical data were expressed as
mean and standard deviation or median and range as appro-
priate. Qualitative data were expressed as frequency and
percentage. Chi-square test (Fisher’s exact test) was used to
examine the relation between qualitative variables. For
quantitative data, comparison between two groups was done
using Mann-Whitney test. OS was estimated from date of
diagnosis till death while DFS from first date showing objec-
tive response (CR/PR) till disease relapse or progression.
Survival analysis was done using Kaplan-Meier method and
comparison between two survival curves was done using
log-rank test. Cox-regression method was used to test survival
for numeric variables and p value < 0.05 was considered sig-
nificant.
Results
Twenty six males and 17 females (1.5:1) were included in the
current study with a median age of 24 months (range: 2
months to 11 years). In 31/43 tumor was located at the right
lobe, 7/43 at the left lobe, and 5/43 had a multifocal hepatic
tumor. Stage I disease was present in 22 (51.2%) of our study
patients, 1 patient (2.3%) had stage II, 16 (37.2%) stage III,
and 4 patients (9.3%) with stage IV disease had lung metas-
tasis at time of presentation. Histological variants included
fetal subtype in 26 (60.5%), embryonal in 4 (9.3%), and mixed
morphology in 13 (30.2%) patients.
Twenty one patients had upfront tumor resection (20 stage I
and 1 stage II) while all stage III and IV patients (n=20) in
addition to another 2 patients with stage I tumor received
neoadjuvant chemotherapy. Eventually, surgical resection
was feasible in 5 initially inoperable patients with stage III
following 4 cycles of chemotherapy and after 2 cycles only in
another 2 patients with stage I disease. Adjuvant postopera-
tive chemotherapy was given to 10 patients for stage I other
than purely fetal and low mitotic index histology and 1 with
stage II disease.
By the end of their upfront treatment (either surgery or ne-
oadjuvant chemotherapy), 20/43 patients (46.5%) attained
complete response (CR) after initial surgery, all of them had
stage I disease whereas 23 patients (53.5%) did not; 7 had
partial response (PR) [1 had stage II with postoperative posi-
tive surgical margins, 2 were stage I and 4 were stage III who
received neoadjuvant chemotherapy], 5 patients showed
disease progression (PD) [4 of them were stage IV and a single
patient had stage III], while 11 stage III patients  had sta-
tionary disease (SD). The 4 years OS and DFS for all patients
under study were 58.2% and 82.4% respectively.
Markers expression
CD44 protein and RNA were reported in 21 (48.8%) and 20
(46.5%) patients respectively; with 85.7% concordance. CD90
protein and RNA were reported in 14 (32.6%) and 18 (41.7%)
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cases respectively; with 77.8% concordance whereas, CD133
protein and RNA were reported in 21 (48.8%) and 25 (58.1%)
patients respectively; with 96% concordance [Figure 1]. For
statistical purposes, only cases showing both protein and RNA
expression were scored positive. Increased expression of all
studied markers (CD44, CD90, CD133) was significantly
correlated with; higher disease stages III and IV versus stages
I and II (p < 0.001); and with poor response to treatment
PR/SD/DP in comparison to CR (p < 0.001).
FIG.1 (A-D): Cases of hepatoplastoma showing positive membra-
no-cytoplasmic immunostaining for CD44 (A), CD90 (B), CD133 (C),
and a negative control (D). (E&F): RT/PCR analysis of CD44, CD90
and CD133 with GAPDH as a housekeeping gene in the hepatoblas-
toma cases.
Survival correlations
The OS was significantly correlated with disease stage (p <
0.001). Patients underwent total surgical tumor resection (12
segmentectomy &12 lobectomy) showed a significantly better
OS compared to those who had incomplete or no resection (p
< 0.001; Table 1).
As regards CSC markers expression, cases with positive CD90,
CD133, and CD44 expression (each or all) showed a signifi-
cantly lower OS than negative cases (p < 0.001; Figure 2),
whereas only CD133 and CD44 expression were significantly
correlated with DFS (p = 0.03 and p < 0.001, respectively)
[Table 1 and Figure 3].
On multivariate analysis, only complete surgical resection
and CD90 expression were independently predictive of OS
(OR 7.9 and 11.8 respectively), whereas CD44 only found to
be an independent prognostic factor for DFS (OR 15.8).
TABLE 1: Correlation of Clinicopathological Variables and CSCs Markers to
Survival at 4 Years
Overall Survival Disease Free Survival



















































































































*No patients available at the predicted time interval.
**No relation could be made as response is a base of entry for DFS
***Small number of patients in sub-groups. CSCs: cancer stem cells,
CR: complete response, PR: partial response, SD: stable disease, PD:
progressive disease, CD: cluster determinant
FIG. 2: Overall survival for HB patients in relation to CD44, CD90 &
CD133 (p < 0.001).
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FIG. 3:Disease free survival for hepatoblastoma patients in relation to
CD44, CD90 and CD133 expression (p < 0.001).
Discussion
Hepatoblastoma is a childhood liver cancer associated with
several prognostic and predictive factors. To date, only few
available case–control studies on small sample sizes discussing
these factors including the premature birth, very low birth
weight, histology subtype and disease stage.22-23
Matched to our results, males are affected more than females
with HB despite possible ethnic variability in the United
States.19 The prognostic impact of the pure fetal histological
HB subtype was shown by other investigators to be associated
with  lower stages, more resectability,  and better survival.22
In our study, patients with pure fetal histology had nominally
higher OS rate (68.7%) compared to those with other histo-
logical subtypes (41.8%) but was not of statistical significance
(p = 0.46). The lack of any significant difference among our
patients could be attributed to the small number of patients
within subgroups.
Although complete surgical resection is considered as the
most important factor predicting patients who would achieve
cure, yet chemotherapy response may also represent an im-
portant factor influencing survival in those patients.24
As recommended by the German group of Pediatric Oncology
Hematology (GPOH) that primary resection in small liver
tumors should be always attempted, investigators from Japan
similarly favored the use of initial surgical resection when-
ever feasible followed by adjuvant chemotherapy to minimize
overall chemotherapy exposure and toxicity.8,25On the con-
trary, the Childhood Liver Tumors Strategy Group (SIOPEL)
group has used the strategy of delayed surgery following
initial chemotherapy in order to make the tumor smaller in
size, less prone to bleed, and thus more likely to be com-
pletely resected.26
By the 1990s, the overall survival for HB had increased from
35% to 70% and has further increased to nearly 80% in the
most recent trials. In some series overall survival was more
than 90% for a localized disease.24 In two recent studies, a
long-term survival in patients with advanced disease stages
ranged from 30% to 60% using systemic chemotherapy.8
Patients with advanced stages (III&IV) in our study had 30%
OS in contrast to those with a more localized disease (stage
I&II) showing a significantly better OS (81.9%); (p < 0.001).
The better survival outcome in patients with early stage dis-
ease could be partly attributed to the fact that those patients
were usually amenable to surgical resection of their tumors.
In accordance, OS of our patients with total surgical resection
was superior to those with incomplete or no resection (83.8%
vs. 25.2% respectively; p < 0.01). The impact of tumor re-
sponse on the OS was also shown in our study [Table 1].
The CSCs detected in several adult tumors, are characterized
by multipotency, self-renewal, proliferation and maintenance
of the neoplastic clone. Suggested role for CSCs in resistance
to conventional chemo- and radiotherapy might be respon-
sible for the aggressive behavior of these tumors. Therefore,
therapies targeted to CSC markers and their mechanisms of
resistance is an area of extensive research.27,28 In HB, a side
population (SP) was successfully isolated from a HB cell line
which was able to form tumors in mice whereas tumors did
not develop  in the non-SP inoculated mice.13,29 However, a
single study has been done on human clinical samples which
included HCC and 4 HB cases, of which one case only was
positive for CSC markers.14 In the current study the CSC
markers CD44, CD90 and CD133 proteins; were respectively
expressed in 48.8%, 32.6% and 58.1% of the cases, compared
to 46.5%, 32.6% and 41.7% for RNA. The expression of these
markers was significantly associated with advanced disease
stage, poor response to treatment and reduced survival indi-
cating that these markers could be used as surrogate markers
in HB patients and for targeted therapy which has been pre-
viously reported in other solid tumors but not in HB.30
Conclusion
Localized disease in hepatoblastoma is associated with a
higher OS than the more advanced stages III and IV whereas,
complete surgical resection of the primary tumor facilitated
with preoperative chemotherapy in initially irresectable cases
can improve the survival outcome in such patients. Some CSC
markers (CD133, 44, and 90) were found to be predictive of
both overall survival and response to treatment, however
further studies are needed to confirm their prognostic role
and their potential value as therapeutic targets.
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